• Site preparation milestone moves Codis’ commercial-scale spray drying expansion into the construction phase
  • New GEA Pharma-SD® type PSD-4 will expand solvent-based spray drying capacity for amorphous solid dispersions
  • Investment will utilize existing infrastructure at Haverhill, supporting an efficient route to increased commercial-scale capacity
  • Expansion strengthens Codis’ U.K. pathway from formulation development through to commercial-scale manufacturing

 

HAVERHILL, UNITED KINGDOM, 29 October 2026 – Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs) and advanced particle engineering, today announced a key milestone in the ongoing PSD-4 expansion at the company’s site in Haverhill, U.K.

The demolition of the existing redundant facilities is now complete, and makes space for the construction of the new building. The construction milestone marks the next stage of Codis’ investment in a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer. Following installation and validation, the PSD-4 will expand Codis’ commercial-scale solvent-based spray drying capacity for ASDs, enabling pharmaceutical customers to advance poorly soluble drug candidates into larger-scale manufacturing.

Together with the company’s formulation development, analytical, clinical supply and oral solid dose capabilities in Nottingham, the investment will further connect development and manufacturing capabilities across Codis’ U.K. network, supporting programs as they progress from early formulation through to commercial-scale spray drying.

“Completing demolition and moving into construction is an important milestone for the PSD-4 expansion. By building within our existing Haverhill facility and utilizing established site infrastructure, we can deliver the additional capacity efficiently while building on the expertise and capabilities already in place in our 100,000 sq. ft. cGMP facility,” commented Nick Hodgson, Vice President & General Manager, Haverhill Operations.

The PSD-4 expansion remains on schedule, with the next key milestone, the Dryer Factory Acceptance Test (FAT), due to take place in November. The new spray dying capacity is expected to become available in the last quarter of 2027.

About Codis

Codis is a global CDMO specializing in commercial spray drying, amorphous solid dispersions, particle engineering, and finished dose manufacturing for the pharmaceutical, consumer health, nutraceutical, and OTC sectors. With more than 400,000 sq ft of cGMP facilities in St. Louis, Missouri, Seymour, Indiana, and Nottingham and Haverhill, UK, Codis combines decades of regulatory expertise, development and manufacturing strength under one brand. Learn more at www.codis.com.